These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 24517415)
21. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy. Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184 [TBL] [Abstract][Full Text] [Related]
22. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177 [TBL] [Abstract][Full Text] [Related]
23. Interferon-λ-related genes and therapeutic response in Chinese hepatitis C patients. Zhang YY; Chen HB; Xu Y; Huang P; Wang J; Zhang Y; Yu RB; Su J World J Gastroenterol; 2015 Apr; 21(13):4006-13. PubMed ID: 25852288 [TBL] [Abstract][Full Text] [Related]
24. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study. Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612 [TBL] [Abstract][Full Text] [Related]
25. Association between IL28B Polymorphisms and Outcomes of Hepatitis B Virus Infection: A meta-analysis. Zhao J; Zhang X; Fang L; Pan H; Shi J BMC Med Genet; 2020 May; 21(1):88. PubMed ID: 32357928 [TBL] [Abstract][Full Text] [Related]
26. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568 [TBL] [Abstract][Full Text] [Related]
27. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020 [TBL] [Abstract][Full Text] [Related]
28. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. Cieśla A; Bociąga-Jasik M; Sobczyk-Krupiarz I; Głowacki MK; Owczarek D; Cibor D; Sanak M; Mach T World J Gastroenterol; 2012 Sep; 18(35):4892-7. PubMed ID: 23002361 [TBL] [Abstract][Full Text] [Related]
29. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment. Fateh A; Aghasadeghi MR; Keyvani H; Mollaie HR; Yari S; Hadizade Tasbiti AR; Ghazanfari M; Monavari SH Asian Pac J Cancer Prev; 2015; 16(5):1873-80. PubMed ID: 25773839 [TBL] [Abstract][Full Text] [Related]
30. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin. Ridruejo E; Solano A; Marciano S; Galdame O; Adrover R; Cocozzella D; Delettieres D; Martínez A; Gadano A; Mandó OG; Silva MO Ann Hepatol; 2011; 10(4):452-7. PubMed ID: 21911885 [TBL] [Abstract][Full Text] [Related]
31. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709 [TBL] [Abstract][Full Text] [Related]
32. Association of interferon-gamma inducible protein 10 polymorphism with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Limothai U; Chuaypen N; Khlaiphuengsin A; Posuwan N; Wasitthankasem R; Poovorawan Y; Tangkijvanich P Antivir Ther; 2016; 21(2):97-106. PubMed ID: 26376789 [TBL] [Abstract][Full Text] [Related]
33. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Moghaddam A; Melum E; Reinton N; Ring-Larsen H; Verbaan H; Bjøro K; Dalgard O Hepatology; 2011 Mar; 53(3):746-54. PubMed ID: 21374656 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C. Jeong SH; Jung YK; Yang JW; Park SJ; Kim JW; Kwon OS; Kim YS; Choi DJ; Kim JH Clin Mol Hepatol; 2012 Dec; 18(4):360-7. PubMed ID: 23323251 [TBL] [Abstract][Full Text] [Related]
35. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. Bochud PY; Bibert S; Negro F; Haagmans B; Soulier A; Ferrari C; Missale G; Zeuzem S; Pawlotsky JM; Schalm S; Hellstrand K; Neumann AU; Lagging M J Hepatol; 2011 Nov; 55(5):980-8. PubMed ID: 21354446 [TBL] [Abstract][Full Text] [Related]
36. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B. Zhu H; Wang C; Zhang Y; Wei S; Li X; Zhang Z J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693 [TBL] [Abstract][Full Text] [Related]
37. Association of vitamin-D-related genetic variations and treatment response to pegylated interferon in patients with chronic hepatitis B. Limothai U; Chuaypen N; Khlaiphuengsin A; Chittmittraprap S; Poovorawan Y; Tangkijvanich P Antivir Ther; 2017; 22(8):681-688. PubMed ID: 28291736 [TBL] [Abstract][Full Text] [Related]
38. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation]. Yue W; Yuan H; Mao XR; Deng YD; Chen L Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738 [TBL] [Abstract][Full Text] [Related]
39. Single nucleotide polymorphisms near IL28B gene and response to treatment of chronic hepatitis C in hemodialysis patients. Dzekova-Vidimliski P; Nikolov IG; Matevska-Geshkovska N; Mena S; Rostaing L; Dimovski A; Sikole A Ren Fail; 2015 Aug; 37(7):1180-4. PubMed ID: 26156685 [TBL] [Abstract][Full Text] [Related]
40. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a]. Luo XD; Chen XP; Chen XF Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):896-901. PubMed ID: 29325289 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]